Universe Pharmaceuticals INC
UPC
$4.91
-$0.21-4.10%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -26.74% | -26.74% | -30.23% | -30.23% | -13.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.74% | -26.74% | -30.23% | -30.23% | -13.17% |
| Cost of Revenue | -22.96% | -22.96% | -22.89% | -22.89% | 23.68% |
| Gross Profit | -35.45% | -35.45% | -45.02% | -45.02% | -48.53% |
| SG&A Expenses | 6.36% | 6.36% | 37.48% | 37.48% | -47.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -73.11% | -73.11% | -123.36% | -123.36% | -5.56% |
| Total Operating Expenses | -8.56% | -8.56% | -20.16% | -20.16% | -31.15% |
| Operating Income | -52.59% | -52.59% | -1,266.35% | -1,266.35% | 59.41% |
| Income Before Tax | 194.10% | 194.10% | -4,901.70% | -4,901.70% | 59.39% |
| Income Tax Expenses | -104.57% | -104.57% | -31.73% | -31.73% | 254.90% |
| Earnings from Continuing Operations | 174.57% | 174.57% | -1,731.34% | -1,731.34% | 43.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 174.57% | 174.57% | -1,731.34% | -1,731.34% | 43.97% |
| EBIT | -52.59% | -52.59% | -1,266.35% | -1,266.35% | 59.41% |
| EBITDA | -56.37% | -56.37% | -466.39% | -466.39% | 60.96% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |